Solid Solution Compositions for Chronic Inflammation via Lipid-Adjuvant Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic inflammation are limited due to the complexity of the inflammatory response and the redundancy of mechanisms involved, with many anti-inflammatory drugs also inhibiting endogenous anti-inflammatory loops, leading to incomplete or prolonged inflammation.
Innovation Solution
Development of solid solution pharmaceutical compositions that utilize a lipid-adjuvant delivery system to effectively inhibit pro-inflammatory responses by formulating therapeutic compounds with room temperature solid and liquid lipids, stabilizing agents, and neutralizing agents, allowing for targeted delivery to cells and tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-inflammatory drugs are used to treat chronic inflammation, then inflammation symptoms are reduced, but endogenous anti-inflammatory loops are also inhibited leading to incomplete or prolonged inflammation resolution
Solution Approach 1:
The patent introduces a lipid-adjuvant delivery system as an intermediary between the therapeutic compound and the inflammatory response. This system selectively delivers the compound to pro-inflammatory cells and tissues, mediating the anti-inflammatory effect while sparing endogenous anti-inflammatory mechanisms. The lipid carrier acts as a selective mediator that targets specific cell types involved in chronic inflammation.
Solution Approach 2:
The invention applies local quality by creating a delivery system with non-uniform distribution properties. The lipid-adjuvant formulation concentrates the therapeutic compound specifically at sites of pro-inflammatory activity while maintaining lower concentrations in tissues where endogenous anti-inflammatory loops operate. This spatially selective distribution allows differential effects on pro-inflammatory versus anti-inflammatory pathways.
2Speed
If the inflammatory response is strongly inhibited to achieve rapid symptom relief, then acute inflammation is controlled, but chronic inflammation mechanisms are not fully addressed due to response complexity
Solution Approach 1:
The patent employs parameter changes by modifying the physical and chemical properties of the therapeutic compound through lipid-adjuvant formulation. This changes the pharmacokinetic parameters (absorption, distribution, metabolism, excretion) and pharmacodynamic parameters (selectivity, potency, duration) of the compound. The formulation transforms a potentially non-selective drug into one with enhanced tissue penetration and cell-type specificity, enabling both rapid and sustained anti-inflammatory effects.
Solution Approach 2:
The invention uses composite materials by combining the therapeutic compound with lipid-adjuvant carriers. This composite formulation integrates the pharmacological activity of the compound with the targeted delivery capabilities of the lipid system. The composite structure allows simultaneous achievement of rapid symptom relief through efficient drug release and reliable chronic inflammation treatment through sustained targeted delivery.
3Reliability
If a lipid-adjuvant delivery system is developed to selectively inhibit pro-inflammatory responses, then treatment effectiveness is improved, but formulation complexity increases
Solution Approach 1:
The lipid-adjuvant delivery system exhibits universality by performing multiple functions simultaneously: it serves as a solubilizer for the therapeutic compound, a targeted delivery vehicle to pro-inflammatory tissues, a stability enhancer, and a controlled-release mechanism. This multi-functionality reduces the need for separate formulation components and simplifies the overall formulation approach despite the advanced capabilities achieved.
Data Source
AI summary
The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.